Stock·NASDAQ·Healthcare
Biogen Inc. (BIIB)
- Market cap
- $37.27B
- P/E
- 44.88
- Dividend yield
- None
- Street target
- $246.50median of 36 analysts
- 52-week range
- $138.00 $254.41
BIIB stock forecast today
Where BIIB stands today, and what CleaRank Financial AI makes of it.
BIIB at a glance
Biogen Inc. (BIIB): Buy, 69/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($224.23 and $199.78).
- Earnings BIIB beat estimates in 8 of its last 8 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $1.8M and bought $152K over the last 18 months.
- Valuation P/E of 44.9 against 31.9 for the Healthcare sector: a premium to peers (+41%).
Figures as of October 26, 2026.
CleaRank Financial AI
Biogen Inc. (BIIB) carries a CleaRank rating of Buy and a model score of 69/100.
Trend contributes the most to that score: the price is 26.27% above its 200-day average, 12.50% above its 50-day average, and the 50-day average is 12.24% above the 200-day. Valuation pulls hardest in the other direction, with the P/E of 44.88 40.7% above the sector median (a premium to peers) and the P/S of 3.72 9.4% above the sector median. The 50-day average is $224.23 and the 200-day is $199.78. Across the past year, the price climbed 68.30%.
Only on CleaRank
Figures we compute ourselves from BIIB's own price, earnings and insider-filing history. Tap one to see it in context.
BIIB stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $252.26 is 12.5% above the 50-day simple moving average of $224.23.Price above its 200-day average ›
The price is 26.3% above the 200-day simple moving average of $199.78.50-day average above the 200-day ›
The 50-day average ($224.23) is 12.2% above the 200-day average ($199.78), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 98% of its 52-week range, between $138.00 and $254.41.
BIIB share price
Pick a period: each tab shows how far BIIB has moved over it, to the last close.
Today's trading
Where BIIB sits inside today's range and its 52-week range.
BIIB fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/4P/E below the sector median ›
The trailing P/E of 44.88 is 40.7% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 3.72 is 9.5% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $834.6M on revenue of $10.0B, a net margin of 8.3%.Beat estimates in most recent reports ›
BIIB beat the EPS estimate in 8 of its last 8 reports.
Key statistics
The headline figures for BIIB.
As of October 26, 2026, BIIB trades at $252.26, with a market value of $37.27B and a P/E ratio of 44.88.
What the numbers say
CleaRank Financial AI's reading of BIIB's valuation, growth and risks.
BIIB's trailing P/E of 44.88 is set against a Healthcare median of 31.9, leaving it 40.7% above that median. The peer comparison on this page places the P/E at a premium to peers. To put the size of the company in context, its market capitalisation is $37.3B.
With revenue growth of 3.40%, BIIB is 4.7 percentage points slower than the sector median of 8.1%. Profitability shows a net margin of 8.32% and an operating margin of 25.06%, with a return on equity of 4.58%, below the sector median of 7.3%. The balance sheet rounds out the picture, with debt-to-equity of 0.44.
Biogen Inc. (BIIB) beat estimates with EPS of $3.60, against an analyst estimate of $2.03, in the July 29, 2026 report. That was a beat of 77.34%. Even so, the share price dropped 0.62% in the following session.
Across its last 8 reports, BIIB beat the estimate every time, but beats have not guaranteed gains: the stock fell the next day after 4 of them. Looking ahead, analysts expect EPS of $12.36 this fiscal year (a decline of 19.1%) and $16.44 the year after (growth of 33.0%).
The P/E of 44.88, 40.7% above the sector median, puts BIIB at a premium to peers, so weaker results would meet a higher bar. On a typical day the price of BIIB shifts by 1.73%, the 30-day standard deviation of its daily returns with a beta of 0.09 against the S&P 500. Insiders sold $1.8M over the last 18 months and bought $152K, though sales of this kind are often planned in advance and say less than purchases would.
BIIB against the Healthcare sector
How BIIB compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: BIIB trades at a significant premium to sector peers (+41%), suggesting market expectations for superior growth or market position.
Return vs XLV: Since May 14, 2025, BIIB has gained 109.6% against a gain of 39.2% for XLV.
Performance against XLV
BIIB and the Healthcare sector fund over the same days.
Revenue and earnings
How much BIIB sells, and how much of it becomes profit.
Revenue growth: Revenue grew 2.2% in FY2025 to $9.9B, from $9.7B a year earlier.
Profit margin: The net margin was 13.1% in FY2025, down from 16.9% the year before.
Profitable: BIIB earned $1.3B in FY2025.
Earnings reality check
Did BIIB beat what analysts expected, and how did the stock react?
Earnings record: BIIB beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 4 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 29, 2026after close | $2.03 | $3.60 | +77.34% | -0.62% | -1.24% |
| Apr 29, 2026after close | $2.95 | $3.57 | +21.02% | -2.62% | -1.90% |
| Feb 6, 2026after close | $1.62 | $1.99 | +22.84% | -3.66% | -2.32% |
| Oct 30, 2025after close | $3.88 | $4.81 | +23.97% | +3.11% | +4.77% |
| Jul 31, 2025after close | $3.88 | $5.47 | +40.98% | +3.09% | -0.20% |
| May 1, 2025after close | $2.95 | $3.02 | +2.37% | +2.15% | -2.10% |
| Feb 12, 2025after close | $3.36 | $3.44 | +2.38% | +3.76% | +2.74% |
| Oct 30, 2024after close | $3.79 | $4.08 | +7.65% | -3.96% | -3.74% |
As of October 26, 2026, BIIB has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on July 29, 2026, came in 77.34% above the estimate and the stock moved -0.62% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
BIIB AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 71.5, in overbought territory.RSI above 50 ›
An RSI of 71.5 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of BIIB
The score, the reasoning behind it, and what could move the price next.
Biogen Inc. (BIIB) is trading at $252.26, above both of its main moving averages. The price is 12.50% above its 50-day average of $224.23 and 26.27% above its 200-day average of $199.78. It sits near the top of its 52-week range: 0.85% below the high of $254.41 and 82.80% above the low of $138.00. The 50-day average is 12.24% above the 200-day, a configuration that backs up the upward move instead of working against it.
Momentum is running hot: the 14-day RSI sits at 71.5, which is in overbought territory, while the MACD line is positive. Returns have been strong across every window, with the price up 26.04% over three months, 39.62% over six months and 68.30% over the past year. Last session's volume came in 29.7% below its average even though the price climbed 0.63% that day.
Analyst upgrade ›
JP Morgan upgraded it to Overweight from Neutral on October 12, 2026.
Source: Analyst action, JP Morgan, October 12, 2026
Earnings beat, but the stock fell ›
The July 29, 2026 report beat the EPS estimate by 77.34%, and the share price fell 0.62% in the first session after it.
Source: Earnings report, July 29, 2026Rating reaffirmed ›
B of A Securities kept its Neutral rating on October 22, 2026.
Source: Analyst action, B of A Securities, October 22, 2026
- The two levels to track are the 52-week high of $254.41, just above the price, and the 20-day EMA at $235.36, just below it.
- A 14-day RSI of 71.5 places the stock in the overbought zone, and the MACD line is positive. Readings above 70 or below 30 point to stretched momentum.
- Following the July 29, 2026 report, the share price slipped 0.62% in the first session, even though BIIB has beaten estimates in 8 of its last 8 reports.
The uptrend rests on BIIB staying above its 50-day average at $224.23 and its 200-day average at $199.78; a close below the 50-day would be the first crack in it. On a pullback, the first level the price would meet is the 20-day EMA at $235.36.
The 52-week high at $254.41 is the next level overhead. The RSI is stretched above the overbought line, so a cooling of momentum would not be unusual even inside the uptrend.
Technical indicators
Momentum and trend for BIIB, from its daily closes.
As of October 26, 2026, with BIIB at $252.26, its 14-day RSI is 71.5 (overbought territory), its 50-day simple moving average is $224.23 and its 200-day is $199.78.
Calculated by CleaRank on daily closes as of October 26, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What BIIB moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 26, 2026, BIIB's 1-year correlation of daily returns is +0.26 with S&P 500 (SPY), +0.16 with Nasdaq 100 (QQQ), +0.00 with Bitcoin (BTC) and +0.00 with gold (XAU).
BIIB price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
24 of 36 analysts rate it a buy or strong buy, 11 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $246.50 is 2.3% below the price.More buy ratings than three months ago ›
24 of 36 rate it a buy now, against 23 of 36 three months ago.
BIIB Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 22, 2026 | B of A Securities | Maintains | Neutral |
| Oct 21, 2026 | TD Cowen | Maintains | Buy |
| Oct 20, 2026 | Wells Fargo | Maintains | Overweight |
| Oct 12, 2026 | JP Morgan | Upgrade | Overweight |
| Oct 9, 2026 | UBS | Maintains | Buy |
| Oct 8, 2026 | RBC Capital | Maintains | Outperform |
As of October 26, 2026, 36 Wall Street analysts cover BIIB: 24 rate it a buy or strong buy, 11 a hold and 1 a sell or strong sell. Their 12-month price targets range from $175.00 to $310.00. The median BIIB price target is $246.50, 2.3% below the price of $252.26.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
BIIB trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
BIIB trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from BIIB's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much BIIB tends to move, against the market and on its own.
BIIB price history and drawdowns
BIIB's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 1.73% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 72.1%, from June 2021 to April 2025; the price is still 38.0% below that peak.Most 1-year holds ended higher ›
45% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $8,672, against $42,015 in the S&P 500 (SPY).
BIIB Drawdowns & Recovery
As of October 26, 2026, BIIB's worst peak-to-trough fall over the last 10 years with dividends reinvested was -72.1% (June 2021 to April 2025); it is still 38.0% below that peak, and 45% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into BIIB in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: BIIB trailed the S&P 500 over this period: $8,672.01 against $42,015.
A $10,000 investment in BIIB in October 2016 would be worth about $8,672 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to BIIB, and which have not.
Strongest month, June: an average of +3.22%, up in 6 of 10 years.
Weakest month, March: an average of -4.84%, up in 2 of 10 years.
This month, October: has averaged -0.06%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, BIIB's strongest calendar month has been June (average +3.22%, up in 6 of 10 years) and its weakest March (average -4.84%, up in 2 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
BIIB stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in BIIB, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in BIIB today could grow to about $10,960 by 2030 in the base case, with a 90th-percentile outcome near $30,627 and a 10th-percentile outcome around $3,922. Projections are statistical simulations, not guarantees.
BIIB Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $276 for BIIB by 2030 in the base case, from $252 today (1.1x over 4 years). The 10th-percentile path ends near $98.94. These are outcomes of a Monte Carlo simulation run on BIIB's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $154 | $258 | $431 | |
| 2028 | $128 | $264 | $546 | |
| 2029 | $111 | $270 | $658 | |
| 2030 | $98.94 | $276 | $773 |
Method: a lognormal simulation of BIIB's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
BIIB insider trading
What the people running the company have bought and sold.
BIIB insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $152K on the open market and sold $1.8M.
As of October 26, 2026, BIIB insiders reported 6 open-market sales worth $1.8M and 2 open-market purchases worth $152K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Sean Godbout
Officer
|
Grant | 27 | - |
| Aug 4, 2026 | Lloyd B. Minor
Director
|
Sell | 1.2K | $239.8K |
| Jun 9, 2026 | Maria C Freire
Director
|
Grant | 2.0K | - |
| Jun 9, 2026 | William A Hawkins III
Director
|
Grant | 1.5K | - |
| Jun 9, 2026 | Susan Langer
Director
|
Grant | 1.5K | - |
| Jun 9, 2026 | Jesus B Mantas
Director
|
Grant | 1.5K | - |
| Jun 9, 2026 | Lloyd B. Minor
Director
|
Grant | 1.5K | - |
| Jun 9, 2026 | Menelas N Pangalos
Director
|
Grant | 2.4K | - |
| Jun 9, 2026 | Menelas N Pangalos
Director
|
Grant | 1.5K | - |
| Jun 9, 2026 | Monish D Patolawala
Director
|
Grant | 1.5K | - |
| Jun 9, 2026 | Eric K. Rowinsky
Director
|
Grant | 1.5K | - |
| Jun 9, 2026 | Stephen A Sherwin
Director
|
Grant | 1.5K | - |
| May 1, 2026 | Adam James Keeney
Officer
|
Grant | 939 | - |
| Apr 1, 2026 | Sean Godbout
Officer
|
Grant | 181 | - |
| Feb 12, 2026 | Nicole Murphy
Officer
|
Buy | 3 | $585 |
| Feb 9, 2026 | Priya Singhal
Officer
|
Sell | 2.7K | $531.5K |
| Feb 6, 2026 | Susan H Alexander
Officer
|
Grant | 9.0K | - |
| Feb 6, 2026 | Sean Godbout
Officer
|
Grant | 1.1K | - |
| Feb 6, 2026 | Ginger Gregory
Officer
|
Grant | 7.2K | - |
| Feb 6, 2026 | Jane Grogan
Officer
|
Grant | 3.3K | - |
| Feb 6, 2026 | Rachid Izzar
Officer
|
Grant | 6.9K | - |
| Feb 6, 2026 | Adam James Keeney
Officer
|
Grant | 5.1K | - |
| Feb 6, 2026 | Robin C. Kramer
Chief Financial Officer
|
Grant | 5.0K | - |
| Feb 6, 2026 | Nicole Murphy
Officer
|
Grant | 8.7K | - |
| Feb 6, 2026 | Priya Singhal
Officer
|
Grant | 6.9K | - |
| Feb 6, 2026 | Christopher Viehbacher
Chief Executive Officer
|
Grant | 24.5K | - |
| Feb 2, 2026 | Priya Singhal
Officer
|
Sell | 748 | $134.1K |
| Jan 30, 2026 | Priya Singhal
Officer
|
Grant | 1.8K | - |
| Dec 1, 2025 | Christopher Viehbacher
Chief Executive Officer
|
Grant | 7.0K | - |
| Oct 31, 2025 | Jane Grogan
Officer
|
Grant | 695 | - |
| Oct 2, 2025 | Sean Godbout
Officer
|
Grant | 26 | - |
| Sep 2, 2025 | Priya Singhal
Officer
|
Sell | 517 | $69.0K |
| Aug 29, 2025 | Priya Singhal
Officer
|
Grant | 1.7K | - |
| Jul 8, 2025 | Rachid Izzar
Officer
|
Sell | 2.2K | $300.1K |
| Jun 17, 2025 | Caroline D Dorsa
Director
|
Grant | 3.2K | - |
| Jun 17, 2025 | Maria C Freire
Director
|
Grant | 2.4K | - |
| Jun 17, 2025 | William A Hawkins III
Director
|
Grant | 2.4K | - |
| Jun 17, 2025 | Susan Langer
Director
|
Grant | 2.4K | - |
| Jun 17, 2025 | Jesus B Mantas
Director
|
Grant | 2.4K | - |
| Jun 17, 2025 | Lloyd B. Minor
Director
|
Grant | 2.4K | - |
| Jun 17, 2025 | Monish D Patolawala
Director
|
Grant | 2.4K | - |
| Jun 17, 2025 | Eric K. Rowinsky
Director
|
Grant | 2.4K | - |
| Jun 17, 2025 | Stephen A Sherwin
Director
|
Grant | 2.4K | - |
| May 19, 2025 | Priya Singhal
Officer
|
Sell | 3.8K | $480.5K |
| May 2, 2025 | Caroline D Dorsa
Director
|
Buy | 1.2K | $151.6K |
| May 1, 2025 | Adam James Keeney
Officer
|
Grant | 938 | - |
Source: TwelveData, from SEC Form 4 filings
BIIB stock forecast: questions people ask
Answered from the figures on this page, as of October 26, 2026.